Cancer Immunology – Products

UChicago and Terumo BCT achieve the first automated 3-in-1 TCR-T workflow on Quantum Flex, accelerating consistent cell therapy production.

TRANSCAN-3 advances personalized T-cell therapies for esophageal cancer with progress in neoantigen discovery and T-cell isolation.

Moleculent’s Techstart program gives researchers early access to its high-plex platform for mapping direct cell-cell interactions in FFPE tissues.

Amsbio expands its CAR-T cell line and protein portfolio to accelerate cancer therapy development.

PHC Corporation’s LiCellMo live cell analyzer wins 2025 R&D 100 Award for advancing real-time metabolic pathway research.

Sino Biological introduces anti-Whitlow 218 linker antibodies for universal, accurate CAR detection in CAR-T development.

This application note explores how advanced SFM formulations can dramatically improve CRISPR-modified CAR-T cell production while maintaining GMP compliance and scalability.

Phylloceuticals has produced its first plant-based PD-1 inhibitor monoclonal antibody only 12 weeks after launching operations in Rapid City, SD.

Xcell Biosciences collaborates with Thermo Fisher to advance Treg and TIL therapies for autoimmune and solid tumor diseases.

Waters Corporation has acquired Halo Labs, a specialist in imaging technologies for detecting and analyzing particles in therapeutic products, including cell, protein, and gene therapies.